November 13, 2025

Understanding how cells interact in their native context is critical for the development of novel therapeutics and effective diagnostics. Conventional assays or single-cell approaches often miss this layer of information, either by averaging signals across the tissue or by removing cells from their tissue environment. Spatial biology, on the other hand, preserves tissue architecture, allowing researchers to study cell type, location, and interaction together to reveal a more complete picture of disease biology.
Spatial biology provides researchers with insights that can directly inform therapeutic development and translational decision-making. By combining cellular detail with spatial context, it enables teams to:
Spatial biology methods generate exceptionally rich datasets that capture multiple layers of tissue complexity. One of the more common spatial biology approaches is multiplex immunofluorescence (mIF), which enables multiple markers to be visualized on a single tissue section. While these datasets bring enormous value, their size and complexity can make them difficult to interpret. When multiple imaging platforms are in use, workflows can become fragmented, and researchers risk generating data that cannot easily be integrated, slowing discovery and translation.
Realizing the full value of spatial biology requires standardized multiplex immunofluorescence protocols and structured workflows that can handle complex datasets and deliver clear, interpretable insights.
To simplify mIF workflows, CellCarta developed SPARTA (Spatial Phenotyping and Analysis in Regions of Tissue with AI)—a platform-agnostic framework that standardizes how datasets are processed and analyzed across imaging systems.
SPARTA incorporates:
By combining platform flexibility, advanced analytics, and tailored reporting, the SPARTA framework ensures that data from different platforms is processed consistently, so researchers can more easily extract meaningful patterns from complex datasets.
By revealing the organization of complex tissue environments and capturing cellular interactions, spatial biology continues to provide critical insights that shape drug development. mIF makes it possible to generate rich, multi-dimensional datasets that inform preclinical research and translational decisions. With structured workflows like SPARTA, supported by strong expertise and collaborations across assay development, pathology, imaging, and data science teams, this data can be transformed into tailored outputs that can help accelerate discovery, strengthen biomarker programs, and support clinical development.
About the author
Yannick Waumans is Executive Director of Histopathology Operations at CellCarta, where he oversees the Histopathology Lab Services, Technical Transfer Office, and Digital Pathology Solutions. With a PhD in Pharmaceutical Sciences and over a decade of experience in histopathology, imaging, and image analysis, Yannick is an expert in advancing and operationalizing digital pathology technologies.
He is especially passionate about leveraging digital pathology to accelerate research and improve clinical outcomes.
Posters
October 30, 2025
More infoPosters
October 30, 2025
More infoCellTalk Blog
October 22, 2025
More info